COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

NIH Seeks Input on Prioritizing Renewable Affinity Reagents

The National Institutes of Health (NIH) is seeking community input on a priority list for renewable affinity reagents for human transcription factors. For more information or to provide input, please visit,

This outreach effort is part of the Protein Capture Reagents Program. This program was initiated by the NIH Common Fund in response to concerns raised by scientific community regarding the lack of access to well-characterized, analytically validated and affordable renewable protein capture reagents.

This is a pilot program that aims to evaluate if a community resource of high quality, renewable affinity reagents can be economically generated and validated for all human proteins, and to develop technologies that will lead to next generation platforms for producing renewable protein capture reagents. This pilot effort includes the generation of affinity reagents (monoclonal antibodies and recombinant Fabs) against all human transcription factors as a test case.